<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02593188</url>
  </required_header>
  <id_info>
    <org_study_id>161406</org_study_id>
    <nct_id>NCT02593188</nct_id>
  </id_info>
  <brief_title>Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)</brief_title>
  <official_title>Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the proposed study is to acquire additional data (including the assessment of
      anti-rHuPH20 antibodies) on the long-term safety of HYQVIA and to assess the prescribed
      treatment regimens and treatment administration in routine clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 12, 2015</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of all related serious adverse events (SAEs)</measure>
    <time_frame>Throughout the study period of approximately 5 1/2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of all SAEs</measure>
    <time_frame>Throughout the study period of approximately 5 1/2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of non-serious adverse events (AEs), related and not related, local and systemic.</measure>
    <time_frame>Throughout the study period of approximately 5 1/2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Infections</measure>
    <time_frame>Throughout the study period of approximately 5 1/2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and titer of binding and neutralizing antibodies to rHuPH20</measure>
    <time_frame>Throughout the study period of approximately 5 1/2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Regimen: Total dose administered</measure>
    <time_frame>Throughout the study period of approximately 5 1/2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Regimen: Infusion interval</measure>
    <time_frame>Throughout the study period of approximately 5 1/2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Administration: Actual volume per infusion</measure>
    <time_frame>Throughout the study period of approximately 5 1/2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Administration: Maximum infusion rate</measure>
    <time_frame>Throughout the study period of approximately 5 1/2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Administration: Mean rate of infusion</measure>
    <time_frame>Throughout the study period of approximately 5 1/2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Administration: Duration of infusion</measure>
    <time_frame>Throughout the study period of approximately 5 1/2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Administration: Number of infusion sites per infusion</measure>
    <time_frame>Throughout the study period of approximately 5 1/2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Health Related Quality of Life: Short Form-36 (SF-36)</measure>
    <time_frame>Every 3 months in first year of study, annually for remainder of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Health Related Quality of Life: EuroQol 5-Dimension (EQ-5D) Questionnaire</measure>
    <time_frame>Every 3 months in first year of study, annually for remainder of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Health Related Quality of Life: Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9)</measure>
    <time_frame>Every 3 months in first year of study, annually for remainder of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Health Related Quality of Life: Treatment Preference Questionnaire</measure>
    <time_frame>Annually throughout the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Health resource use: hospitalizations</measure>
    <time_frame>Throughout the study period of approximately 5 1/2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Health resource use: length of hospital stay</measure>
    <time_frame>Throughout the study period of approximately 5 1/2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Health resource use: acute care visits</measure>
    <time_frame>Throughout the study period of approximately 5 1/2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Health resource use: Emergency Room visits</measure>
    <time_frame>Throughout the study period of approximately 5 1/2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Days missed from work/school</measure>
    <time_frame>Throughout the study period of approximately 5 1/2 years</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">264</enrollment>
  <condition>Primary Immunodeficiency Diseases (PID)</condition>
  <arm_group>
    <arm_group_label>HYQVIA- Epoch 1</arm_group_label>
    <description>Participants receiving HYQVIA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HYQVIA- Epoch 2</arm_group_label>
    <description>Participants with rHuPH antibody titers â‰¥160 (tested in Epoch 1)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HYQVIA</intervention_name>
    <description>Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase</description>
    <arm_group_label>HYQVIA- Epoch 1</arm_group_label>
    <arm_group_label>HYQVIA- Epoch 2</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples (plasma) for antibodies against recombinant human hyaluronidase (rHuPH20) that
      remain after study testing will be stored at the Central Laboratory to confirm implausible or
      critical test results, if required. Samples will be stored in a coded form and according to
      local requirements for a maximum of 2 years after the final study report has been completed
      and subsequently will be destroyed.
    </textblock>
  </biospec_descr>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant requires immunoglobulin treatment for primary immunodeficiency disease
             (PIDD)

          2. Participant age is compatible with local package insert requirements

          3. Participant has been prescribed or has started treatment with HYQVIA (Immune Globulin
             (Human) 10% with rHuPH20)

          4. Participant is willing and able to comply with the requirements of the protocol.

          5. Female participant of child-bearing potential agrees to inform the investigator if she
             becomes pregnant, or plans to become pregnant during the course of the study

        Exclusion Criteria:

          1. Participant has known hypersensitivity to any of the components of the medicinal
             product

          2. Participant has participated in an interventional clinical study involving a medicinal
             product or device within 30 days prior to enrollment or is scheduled to participate in
             an interventional clinical study involving a medical product or device during the
             course of this study

          3. Participant is a family member or employee of the investigator

          4. Participant is planning to become pregnant, pregnant or breastfeeding at the time of
             enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shire Director</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kern Allergy Medical Clinic</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Irvine Medical Center</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riviera Allergy Medical Center</name>
      <address>
        <city>Redondo Beach</city>
        <state>California</state>
        <zip>90277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Allergy &amp; Respiratory Disease Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA School of Medicine</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma and Allergy Associates, PC</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pikes Peak Allergy and Asthma</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMMUNOe International Research Centers</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <zip>80233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Pollens Clinical Research Centers, Inc.</name>
      <address>
        <city>Albany</city>
        <state>Georgia</state>
        <zip>31707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Childrens Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canton Health Center</name>
      <address>
        <city>Canton</city>
        <state>Michigan</state>
        <zip>48187-5097</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corning Center for Clinical Research</name>
      <address>
        <city>Corning</city>
        <state>New York</state>
        <zip>14830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health, Inc. PRIME</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop University</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Healthcare System</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Asthma &amp; Immunology Relief of Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimed Research, LTD</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy, Asthma and Clinical Research Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OK Institute of Allergy &amp; Asthma Clinical Research, LLC</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vital Prospects Clinical Research Institute, P.C.</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Clinical Immunology Associates</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Allergy, Asthma &amp; Urticaria Centers of Charleston, PA</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29420-4211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy / Immunology Research Center of North Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McKinney Allergy and Asthma Center</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greater Austin Allergy, Asthma, &amp; Immunology</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78664-5226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 29, 2015</study_first_submitted>
  <study_first_submitted_qc>October 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2015</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Shire provides access to the de-identified individual participant data for eligible studies to aid qualified researchers in addressing legitimate scientific objectives. These IPDs will be provided following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.shiretrials.com website. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.shiretrials.com/en/our-commitment-to-transparency/data-sharing-with-researchers</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

